1.18
Opko Health Inc stock is traded at $1.18, with a volume of 2.45M.
It is up +2.61% in the last 24 hours and down -10.61% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.15
Open:
$1.15
24h Volume:
2.45M
Relative Volume:
0.77
Market Cap:
$905.89M
Revenue:
$642.03M
Net Income/Loss:
$-180.42M
P/E Ratio:
-4.7831
EPS:
-0.2467
Net Cash Flow:
$-212.06M
1W Performance:
-3.28%
1M Performance:
-10.61%
6M Performance:
-15.11%
1Y Performance:
-28.05%
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
OPK
Opko Health Inc
|
1.18 | 882.86M | 642.03M | -180.42M | -212.06M | -0.2467 |
|
TMO
Thermo Fisher Scientific Inc
|
513.68 | 193.72B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.52 | 147.88B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
657.38 | 51.84B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.72 | 35.19B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.44 | 32.01B | 3.17B | 642.63M | 516.49M | 10.77 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | JP Morgan | Neutral |
| Oct-31-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
OPKO Health Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Opko Health, Inc. (OPK) Stock Analysis: A Closer Look At Its 209% Potential Upside - DirectorsTalk Interviews
Revenue Check: Is OPKO Health Inc likely to announce a buyback2025 Performance Recap & Growth Focused Entry Reports - baoquankhu1.vn
Brokerages Set OPKO Health, Inc. (NASDAQ:OPK) Target Price at $2.28 - Defense World
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - The Globe and Mail
OPKO Health (OPK) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Finviz
Opko Health, Inc. (OPK) Investor Outlook: Unpacking The 189.30% Potential Upside - DirectorsTalk Interviews
11 Best High Return Penny Stocks to Buy Right Now - Insider Monkey
Esoteric Testing Market: Generated Opportunities and Future - openPR.com
Why OPKO Health Inc. stock is favored by top institutionsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
OPKO Health, Inc. to Announce 2025 Financial Results on February 26, 2026 - Quiver Quantitative
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - OPKO Health, Inc.
What is the long term forecast for OPKO Health Inc. stockWall Street Watch & AI Enhanced Trade Execution Alerts - mfd.ru
OPKO Health Insider Ups Holding During Year - Yahoo Finance
What hedge fund activity signals for OPKO Health Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Opko Health stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
OPKO Health, Inc. (OPK) Stock Analysis: Exploring A 191.67% Potential Upside - DirectorsTalk Interviews
Swing Trade: What is OPKO Health Incs 5 year growth outlookWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Opko Health and Entera Bio expand partnership to advance first-in-class oral long acting PTH tablet for patients with hypoparathyroidism - marketscreener.com
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism - TradingView
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Market Review: Is OPKO Health Inc likely to announce a buybackJuly 2025 Volume & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha
EV Market: Will OPKO Health Inc benefit from seasonality2025 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Analyst Calls: Does RAMP align with a passive investing strategyCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts - MarketBeat
OPKO Health (NASDAQ:OPK) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Update Recap: What is OPKO Health Incs 5 year growth outlookJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Movement Recap: What drives Simulations Plus Incs stock priceQuarterly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Opko Health, Inc. (OPK) Stock Analysis: Exploring A Potential 177.99% Upside - DirectorsTalk Interviews
Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burg... - ADVFN
Options Flow: What is the long term forecast for OPKO Health Inc stockPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health (NASDAQ:OPK) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
OPK: Therapeutics-focused strategy, key partnerships, and innovative pipeline drive growth - TradingView — Track All Markets
Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns - Yahoo Finance
Block Trades: Is OPKO Health Inc forming a double bottom2025 AllTime Highs & Accurate Buy Signal Notifications - baoquankhu1.vn
Assessing OPKO Health (OPK) Valuation After Diagnostics Refocus And Mixed Share Price Performance - Yahoo Finance
What are the future prospects of OPKO Health Inc.Exit Point & Smart Allocation Stock Tips - bollywoodhelpline.com
Opko Health, Inc. (OPK) Stock Analysis: Exploring A 167% Potential Upside For Investors - DirectorsTalk Interviews
Bearish Setup: Should I hold or sell OPKO Health Inc nowWeekly Stock Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):